ABOUT NANOMAB

OVERVIEW

NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of next generation radiopharmaceuticals.

We are developing medicine for fast and specific delivery of radiation to treat cancer. A therapeutic product is made by a camelid antibody labelled with a radioisotope of therapeutic radiation. This therapeutic product is paired with a diagnosis, using the same antibody vector but labelled with a lower radiation radioisotope for imaging. Our goal is to develop a pipeline of theranostic couple camelid antibodies with our proprietary camelid antibodies platform to address the unmet medical need for cancer patients across the world.